Eloxx reports positive kidney biopsy results from Phase 2 ELX-02 trial in Alport syndrome

Eloxx Pharmaceuticals, Inc.

Three patients showed improvement in foot process effacement on TEM kidney biopsies after 8 weeks of ELX-02 treatment.
Patient 4401-02 achieved remission based on Urine-Protein Creatine Ratio (UPCR).
Patient 4402-01 showed wider intact foot process areas, though pre/post comparison was limited.
Company to seek FDA alignment on pivotal trial design and Breakthrough Therapy Designation for ELX-02.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.